Efficacy and Safety of Picosecond, Neodymium-doped Yttrium Aluminum Garnet Laser Therapy Using 1,064 nm and 595 nm

Inclusion Criteria: * Females between the ages of 19 and 74 * Has Fitzpatrick Skin Type III-V * Diagnosed with moderate to severe (GSS ≧ 2) melasma lesions * Agreed to the prohibition of the use of local/systemic corticosteroids or retinoids and other local/systemic lightening medications, and willing to abide by such instructions * Agreed to use the same facial skin care products during the clinical trial period (including the follow-up period), and willing to abide by such instructions * Agreed to the daily use of an over SPF 50 sunblock on their face during the clinical trial period (including the follow-up period), and willing to abide by such instructions * Agreed to have their face photographed * (In case of fertile women) Tested negative in the pregnancy test and agreed to use birth control contraceptives during the clinical trial period * Oral contraceptives are forbidden as they may influence the results of the clinical study. * Agreed not to undergo any other procedure on their face during their participation in the clinical trial * Voluntarily agreed to sign the written consent form and willing to follow the instructions of the study protocol Exclusion Criteria: * Participated in another medical device or medication clinical trial in the last 3 months, or planning to participate in another trial during this trial * Received a cosmetic treatment such as laser, light therapy, or surgery in their facial area in the last 6 months, or have a history of filler treatments using collagen, hyaluronic acid, or any other material * Diagnosed with incurable melisma * Has a history of allergic reaction to local anesthesia * Has a history of malignant tumors on their face * Has skin lesions such as cuts, wounds, or injuries on their face * Pregnant or breastfeeding * Has an infection, dermatitis, or rash on their face * Currently diagnosed with uncontrolled diabetes or a cardiac disorder such as resistant hypertension * Currently diagnosed with anticoagulant disease or taking anticoagulants * Has a history of keloid scarring, hypertrophic scarring, or abnormal would healing * Has a history of immunodeficiency or intake of immunosuppressants * Has a history of leukoplakia, eczema, or psoriasis * Has a history of connective tissue diseases such as systemic lupus erythematosus or scleroderma * Has a history of convulsive disorder caused by light * Has a history of diseases irritated by heat on their face (e.g., herpes simplex or herpes zoster) * Has a history of radiotherapy or anticancer chemotherapy on their face * Has a history of hormonal therapy in the last 3 months (e.g., estrogen, progesterone, or oral contraceptive) * Has a history of use of a lightening medication (hydroquinone, tranexamic acid), isotretinoid (or retinoid), light-sensitive medication, or steroids in the last 6 months * Has excessive facial tanning * Other subject assessed as inadequate for the clinical trial by the investigators